International Journal of Chemical Studies

P-ISSN: 2349–8528
E-ISSN: 2321–4902
www.chemijournal.com
IJCS 2024; 12(5): 144-149

Received: 03-08-2024
Accepted: 11-09-2024

Mahesh Y
[1] Assistant Professor, Department of Chemistry, JVR Govt. College (A), Sathupally, Telangana, India
[2] Department of Pharmaceutical Chemistry Telangana University Dichupally Nizamabad, Telangana, India

Corresponding Author:
Mahesh Y
[1] Assistant Professor, Department of Chemistry, JVR Govt. College (A), Sathupally, Telangana, India
[2] Department of Pharmaceutical Chemistry Telangana University Dichupally Nizamabad, Telangana, India

Recent advances in trifluoromethyl quinazoline derivatives: From antimalarial to antitumor applications

Mahesh Y

Abstract
Quinazoline derivatives have gained significant attention recently due to their diverse biological activities, including anticancer, antiviral, antimicrobial, and antimalarial effects. Among these, trifluoromethyl quinazoline derivatives have emerged as a promising class of compounds with potent therapeutic potential. The trifluoromethyl group (-CF_3) enhances the metabolic stability, lipophilicity, and bioavailability of these molecules, making them attractive for drug development. Trifluoromethyl quinazoline derivatives have been extensively studied for their antitumor properties, with several compounds showing remarkable efficacy in inhibiting cancer cell proliferation by targeting key cellular pathways, including tyrosine kinase inhibition and DNA intercalation. Notably, some derivatives have also been developed into effective antimalarial agents, contributing to the fight against drug-resistant strains of *Plasmodium falciparum*. Despite the progress in clinical applications, challenges such as drug resistance and side effects persist. Therefore, the discovery of new trifluoromethyl quinazoline compounds with improved efficacy and reduced toxicity remains a crucial research focus. This review highlights the recent advances in the synthesis, biological activities, and mechanistic insights of trifluoromethyl quinazoline derivatives, spanning from antimalarial to antitumor applications. We discuss key examples of FDA-approved quinazoline-based drugs, including gefitinib, erlotinib, and afatinib, and explore their relevance in addressing drug resistance. The ongoing efforts in this field aim to develop novel small-molecule anticancer agents that overcome resistance and offer safer alternatives to existing therapies. The incorporation of trifluoromethyl groups holds great promise for enhancing the therapeutic potential of quinazoline derivatives in modern drug discovery.

Keywords: Trifluoromethyl quinazoline, anticancer, antimalarial, drug resistance, tyrosine kinase inhibitors, bioavailability, small-molecule compounds, antitumor activity, quinazoline derivatives, drug discovery

1. Introduction
Quinazoline derivatives have been extensively studied for their wide range of biological activities, including antimalarial and anticancer properties. The trifluoromethyl group (-CF3), when introduced into drug molecules, enhances important pharmacokinetic properties such as metabolic stability, lipophilicity, and bioavailability, all of which are key to therapeutic efficacy (Katritzky & Ramsden, 2008) [5]. This makes trifluoromethyl quinazoline derivatives particularly valuable in the development of treatments for resistant strains of malaria and various cancers.

1.1 Role in Antimalarial Applications
Malaria remains a significant global health issue, especially with the rise of drug-resistant *Plasmodium falciparum* strains. The inclusion of the trifluoromethyl group in quinazoline derivatives has shown significant improvement in antimalarial efficacy. These derivatives work by inhibiting key enzymes in the parasite's life cycle, thereby showing promising activity against drug-resistant strains of malaria (Sharma *et al*., 2018) [8]. Furthermore, these compounds have potential not only as therapeutic agents but also as prophylactic agents, offering a much-needed solution to drug resistance in malaria treatment (Bansal *et al*., 2016) [1].

1.2 Role in Antitumor Applications
Trifluoromethyl quinazoline derivatives have been extensively studied for their antitumor properties, particularly in targeting various cancers.

One primary mechanism through which these compounds exert anticancer effects is by inhibiting receptor tyrosine kinases (RTKs), crucial for processes like cell proliferation and survival (Zhang *et al*., 2013) [18]. Some of the most well-known examples of these derivatives include FDA-approved drugs such as gefitinib and erlotinib, which have demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC) (Woodburn *et al*., 2000) [14].

The antitumor potential of trifluoromethyl quinazoline derivatives is further enhanced by their ability to interact with DNA, induce apoptosis, and inhibit angiogenesis, all of which contribute to their versatility in cancer therapy (Zhao *et al*., 2015) [22]. These drugs also enhance metabolic stability and improve cell membrane permeability, thus reducing the likelihood of developing drug resistance (Gupta *et al*., 2016) [4]. The incorporation of trifluoromethyl groups into quinazoline scaffolds has provided a critical platform for designing novel anticancer agents with increased efficacy and reduced toxicity (Lee *et al*., 2017) [6].

1.3 Addressing Drug Resistance

Drug resistance remains a significant challenge in both malaria and cancer treatment. The incorporation of trifluoromethyl groups into quinazoline derivatives has proven to be a promising strategy to address this issue. In malaria, these compounds target new sites within the parasite, which reduces the likelihood of resistance development (Wells *et al*., 2015) [11]. In cancer, trifluoromethyl quinazoline derivatives have demonstrated effectiveness in overcoming resistance to first-generation tyrosine kinase inhibitors (TKIs), particularly by binding more efficiently to mutant forms of EGFR (Ranson *et al*., 2005) [7]. Trifluoromethyl quinazoline derivatives represent a significant advancement in modern drug development due to their enhanced potency and ability to overcome drug resistance. Their dual applications in both antimalarial and antitumor therapies underscore their versatility and importance in the field of medicinal chemistry. Ongoing research efforts will continue to explore these compounds as potential therapeutic agents, providing hope for future treatments of some of the most challenging diseases, including drug-resistant malaria and cancer.

To explain the content of the review paper on Trifluoromethyl Quinazoline Derivatives (Fig-1) and guide understanding, follow these steps:



Fig 1: derivatives of trifluoromethyl group (-CF_3)

Here is the scientific illustration showcasing the structure of trifluoromethyl quinazoline derivatives, highlighting the quinazoline scaffold and the trifluoromethyl group (-CF_3). The visual emphasizes key molecular components for clarity.

2. Central Concept of Trifluoromethyl Quinazoline Derivatives

The central concept of this review is the exploration of trifluoromethyl quinazoline derivatives, which are a unique class of chemical compounds characterized by the presence of a quinazoline scaffold and a trifluoromethyl group (-CF3) (Table-2). These compounds have garnered considerable attention in medicinal chemistry due to their diverse biological activities, particularly their antimalarial and antitumor properties.

2.1 Trifluoromethyl Group Impact

The introduction of the trifluoromethyl group into quinazoline derivatives significantly enhances their pharmacokinetic properties. Specifically, the trifluoromethyl substitution improves several critical characteristics:

1. **Metabolic Stability:** Compounds with a trifluoromethyl group tend to resist metabolic degradation, prolonging their action in the body (Katritzky & Ramsden, 2008) [5].
2. **Lipophilicity:** The lipophilic nature of these compounds facilitates better membrane penetration, which is crucial for their effectiveness as drugs (Sharma *et al*., 2018) [8].
3. **Bioavailability:** Enhanced bioavailability allows for more efficient drug absorption and utilization, leading to improved therapeutic outcomes (Bansal *et al*., 2016) [1].

2.2 Antimalarial and Antitumor Applications

Recent studies indicate that trifluoromethyl quinazoline derivatives exhibit potent antimalarial activity by inhibiting essential enzymes in the lifecycle of malaria parasites, such as *Plasmodium falciparum*. This is particularly vital in addressing the challenge posed by drug-resistant strains (Wells *et al*., 2015) [11].

In the realm of oncology, these derivatives have shown significant promise as anticancer agents. They primarily exert their effects by inhibiting receptor tyrosine kinases (RTKs), which are key regulators of cell proliferation and survival (Zhang *et al*., 2013) [18]. Noteworthy examples include FDA-approved drugs like gefitinib and erlotinib, which have demonstrated efficacy in treating non-small cell lung cancer (NSCLC) (Woodburn *et al*., 2000) [14]. (Table-1).

The dual functionality of trifluoromethyl quinazoline derivatives targeting both malaria and cancer underscores their importance in drug discovery and development, providing a compelling avenue for further research into their therapeutic potential.

Table 1: Overview of Trifluoromethyl Quinazoline Derivatives and Their Biological Activities

Aspect	Details
Class of Compounds	Trifluoromethyl Quinazoline Derivatives
Structural Characteristics	Contains a quinazoline scaffold and a trifluoromethyl group (-CF3).
Key Functional Group	Trifluoromethyl group (-CF3)
Metabolic Stability	Improves resistance to metabolic degradation, extending the duration of action (Katritzky & Ramsden, 2008) [5].
Lipophilicity	Increases membrane penetration, enhancing drug efficacy (Sharma *et al*., 2018) [8].
Bioavailability	Facilitates better absorption and utilization of the drug, leading to improved therapeutic outcomes (Bansal *et al*., 2016) [1].
Biological Activities	Exhibits antimalarial and antitumor properties, garnering interest in medicinal chemistry.
Antimalarial Applications	Inhibits critical enzymes in the lifecycle of malaria parasites, including *Plasmodium falciparum*, aiding in the fight against drug resistance (Wells *et al*., 2015) [11].
Antitumor Applications	Primarily inhibits receptor tyrosine kinases (RTKs), essential for regulating cell proliferation and survival (Zhang *et al*., 2013) [18].
FDA-Approved Examples	- Gefitinib and Erlotinib: Effective in treating non-small cell lung cancer (NSCLC) (Woodburn *et al*., 2000) [14].
Research Directions	Ongoing studies focus on developing novel derivatives with enhanced potency and reduced toxicity for both cancer and malaria treatment.

3. Identify the Therapeutic Importance

Therapeutic Importance of Trifluoromethyl Quinazoline Derivatives

Trifluoromethyl quinazoline derivatives are gaining prominence in medicinal chemistry due to their significant therapeutic potential, particularly in the following applications:

3.1 Antimalarial Applications

- **Effectiveness against Drug-Resistant Strains:** These derivatives have shown remarkable efficacy in targeting drug-resistant strains of malaria, particularly *Plasmodium falciparum*. They exert their antimalarial effects by inhibiting key enzymes essential for the parasite's lifecycle, thereby disrupting its ability to survive and reproduce (Wells *et al*., 2015) [11].
- **Mechanism of Action:** By targeting critical enzymatic pathways within the malaria parasite, trifluoromethyl quinazoline derivatives provide a promising strategy for combating the increasing prevalence of drug-resistant malaria, thus contributing significantly to global health efforts in malaria treatment (Bansal *et al*., 2016) [1].

3.2 Antitumor Applications

- **Inhibition of Receptor Tyrosine Kinases (RTKs):** Trifluoromethyl quinazoline derivatives are recognized for their ability to inhibit receptor tyrosine kinases, which play a pivotal role in the regulation of cancer cell growth and proliferation (Zhang *et al*., 2013) [18]. This mechanism is crucial for the development of effective cancer therapies.
- **Examples of FDA-Approved Drugs:** Noteworthy compounds in this category include gefitinib and erlotinib, both of which have been approved for the treatment of non-small cell lung cancer (NSCLC). These drugs exemplify the therapeutic success achieved with trifluoromethyl quinazoline derivatives, demonstrating their effectiveness in targeting specific molecular pathways involved in cancer progression (Woodburn *et al*., 2000) [14]. The dual therapeutic applications of trifluoromethyl quinazoline derivatives as antimalarial and antitumor agents underscore their importance in contemporary drug discovery. Their ability to target resistant pathogens and critical cancer pathways highlights their potential as valuable additions to current treatment strategies in both infectious diseases and oncology.

4. Role of the Trifluoromethyl Group (-CF3)

4.1 Role of the Trifluoromethyl Group (-CF3) in Quinazoline Derivatives

The incorporation of the trifluoromethyl group (-CF3) into quinazoline derivatives is pivotal for enhancing their pharmacokinetic properties, which in turn improves the effectiveness of these compounds in both antimalarial and anticancer treatments.

4.1.1 Advantages of the Trifluoromethyl Group (-CF3)

- **Improved Metabolic Stability:** The trifluoromethyl group increases the metabolic stability of drug molecules, meaning they are less likely to be broken down quickly by enzymes in the body. This leads to longer-lasting effects and the potential for lower doses, which can minimize side effects (Katritzky & Ramsden, 2008) [5].
- **Enhanced Lipophilicity and Membrane Permeability:** The-CF3 group boosts the lipophilic nature of these derivatives, allowing them to more easily penetrate biological membranes. This is particularly beneficial for targeting intracellular pathogens like *Plasmodium falciparum* in malaria, as well as cancer cells (Sharma *et al*., 2018) [8].

- **Reduction in Toxicity:** The addition of the trifluoromethyl group has been associated with lower toxicity profiles in both antimalarial and anticancer applications. This can lead to safer treatments with fewer adverse reactions (Bansal *et al*., 2016) [1].

4.2 Disadvantages and Challenges

- **Potential for Drug Resistance**: Although the -CF3 group improves stability and effectiveness, there is still the potential for the development of resistance, especially in the case of antimalarial treatments. Parasites may evolve to overcome the effects of these enhanced molecules over time (Wells *et al*., 2015) [11].
- **Cost and Complexity of Synthesis**: The introduction of trifluoromethyl groups can increase the complexity and cost of synthesizing these compounds. Fluorination is a demanding chemical process, which could limit the large-scale production of these derivatives for widespread use (Sharma *et al*., 2018) [8]. While the trifluoromethyl group provides significant pharmacokinetic advantages like increased metabolic stability, better membrane penetration, and reduced toxicity, challenges such as the risk of drug resistance and the high cost of synthesis remain. These factors should be carefully weighed when developing trifluoromethyl quinazoline derivatives for clinical use.

4.3 Examine the Mechanism of Action in Malaria and Cancer: Mechanism of Action of Trifluoromethyl Quinazoline Derivatives in Malaria and Cancer

Trifluoromethyl quinazoline derivatives exhibit promising therapeutic effects through distinct mechanisms of action in both antimalarial and anticancer treatments.

4.4 Antimalarial Action

Targeting Essential Enzymes: The primary mechanism of action against malaria involves the inhibition of key enzymes critical for the survival and replication of *Plasmodium falciparum*, the most virulent malaria parasite. These enzymes may include:

- **Dihydrofolate reductase (DHFR):** Involved in folate synthesis, essential for DNA synthesis and cellular division.
- **Heme polymerase:** Crucial for detoxifying heme, a byproduct of hemoglobin breakdown. Inhibition leads to the accumulation of toxic heme levels within the parasite.
- **Overcoming Drug Resistance:** The unique structure of trifluoromethyl quinazoline derivatives contributes to their efficacy against drug-resistant strains of malaria. Their ability to target multiple pathways or enzymes within the parasite's lifecycle reduces the likelihood of resistance developing (Wells *et al*., 2015) [11].

4.5 Antitumor Action

Inhibition of Receptor Tyrosine Kinases (RTKs): In cancer treatment, trifluoromethyl quinazoline derivatives primarily target receptor tyrosine kinases (RTKs), which are critical regulators of cell growth, differentiation, and survival. Key actions include:

- **Induction of Apoptosis:** By inhibiting RTKs, these derivatives trigger programmed cell death in cancer cells, effectively reducing tumor size and spread.
- **Disruption of the Cancer Cell Cycle:** The inhibition of RTKs leads to cell cycle arrest, preventing cancer cells from progressing through crucial phases of division, thereby stunting tumor growth.

4.6 Reducing Angiogenesis: Trifluoromethyl quinazoline derivatives also inhibit the formation of new blood vessels (angiogenesis) that supply nutrients and oxygen to tumors. By disrupting the signaling pathways involved in angiogenesis, these compounds limit the tumor's ability to grow and metastasize (Zhang *et al*., 2013) [18]. The dual mechanisms of action of trifluoromethyl quinazoline derivatives against malaria and cancer underscore their therapeutic potential. Their ability to target essential enzymes in malaria and inhibit key signaling pathways in cancer treatment presents significant opportunities for drug development aimed at tackling these global health challenges.

- **Antimalarial Action:** The derivatives target enzymes in the parasite crucial for its survival and replication, thus helping treat drug-resistant malaria.
- **Antitumor Action:** In cancer treatment, these derivatives inhibit RTKs, leading to apoptosis (programmed cell death) and inhibition of cancer cell proliferation. They also disrupt the cancer cell cycle and reduce angiogenesis (formation of blood vessels that feed tumors).

Table 2: Trifluoromethyl Quinazoline Derivatives, Applications, and Mechanisms of Action

Derivative Name	Application	Mechanism of Action	Impact
Gefitinib (Iressa)	Anticancer (non-small cell lung cancer, NSCLC)	Inhibits EGFR tyrosine kinase	Effective in treating NSCLC with EGFR mutations
Erlotinib (Tarceva)	Anticancer (NSCLC, Pancreatic cancer)	Inhibits EGFR tyrosine kinase	Improves survival in NSCLC, especially in EGFR mutation cases
Lapatinib (Tykerb)	Anticancer (Breast cancer)	Dual inhibitor of EGFR and HER2	Used in HER2-positive breast cancer treatment in combination with others
Afatinib (Gilotrif)	Anticancer (NSCLC)	Inhibits EGFR and HER2	Effective in treating drug-resistant lung cancer with EGFR mutations
Dacomitinib (Vizimpro)	Anticancer (NSCLC)	Irreversible EGFR inhibitor	Treats metastatic NSCLC with EGFR mutations
Osimertinib (Tagrisso)	Anticancer (NSCLC)	Inhibits EGFR with T790M mutation	Overcomes resistance to first-generation EGFR inhibitors in NSCLC patients
Selumetinib (KOSELUGO)	Anticancer (Neurofibromatosis type 1)	Inhibits MEK1/2 (RAS/RAF/MEK/ERK signaling pathway)	Treats pediatric patients with inoperable plexiform neurofibromas
CI-1033 (Canertinib)	Anticancer (Breast, ovarian, lung cancer)	Pan-erbB receptor inhibitor targeting EGFR and HER2	Investigated in various solid tumors

5. Review the FDA-Approved Drugs: The paper highlights key FDA-approved quinazoline derivatives used in cancer treatment, specifically:

5.1 Gefitinib and Erlotinib: Both are antitumor drugs primarily targeting non-small cell lung cancer (NSCLC).

These drugs function by inhibiting the epidermal growth factor receptor (EGFR), a receptor that is overexpressed and overactive in certain cancer types. EGFR plays a crucial role in promoting cancer cell growth, survival, and proliferation. By blocking this receptor, gefitinib and erlotinib reduce tumor progression and improve cancer management.

These FDA-approved drugs showcase the therapeutic significance of quinazoline derivatives in oncology, especially in targeting molecular pathways involved in cancer cell proliferation (Woodburn *et al*., 2000; Zhang *et al*., 2013) [14,].

6. Address Drug Resistance

The paper addresses the issue of drug resistance in both malaria and cancer treatments:

In malaria, drug resistance is a significant challenge, especially with *Plasmodium falciparum*. Trifluoromethyl quinazoline derivatives help overcome this problem by targeting novel sites within the parasite, reducing the likelihood of resistance development (Wells *et al*., 2015) [11] [11].

In cancer, particularly in non-small cell lung cancer (NSCLC), resistance to first-generation tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, often develops due to mutations in the epidermal growth factor receptor (EGFR). These quinazoline derivatives have shown effectiveness in treating mutant forms of EGFR, helping to overcome drug resistance and prolonging the efficacy of treatments (Zhang *et al*., 2013) [18].

7. Emphasize the Role of Ongoing Research

Research on trifluoromethyl quinazoline derivatives continues to evolve, focusing on developing new drugs that are more effective, less toxic, and better equipped to overcome drug resistance in both malaria and cancer.

The future therapeutic potential of these compounds lies in their optimization for broader use, aiming to refine their pharmacokinetic properties and enhance their efficacy in antimalarial and anticancer therapies. This ongoing research is crucial for addressing the limitations of current treatments and improving patient outcomes (Sharma *et al*., 2018; Bansal *et al*., 2016) [8, 1].

8. Summarize Key Points

Trifluoromethyl quinazoline derivatives have become central to modern drug discovery, particularly due to their dual therapeutic potential in treating malaria and cancer. These compounds stand out for their antimalarial properties, where they target essential enzymes of malaria parasites like *Plasmodium falciparum*, addressing drug resistance challenges. In cancer therapy, they act by inhibiting receptor tyrosine kinases (RTKs), especially targeting the epidermal growth factor receptor (EGFR), crucial for cancer cell proliferation. The trifluoromethyl group (-CF3) enhances these derivatives' pharmacokinetic properties, including metabolic stability and membrane permeability, leading to improved drug efficacy. Furthermore, ongoing research is focused on refining these compounds to enhance effectiveness, reduce toxicity, and overcome emerging drug resistance.

9. Conclusion

Trifluoromethyl quinazoline derivatives hold immense promise in addressing critical healthcare challenges such as drug-resistant malaria and cancer treatment, particularly non-small cell lung cancer (NSCLC). Their pharmacokinetic benefits, combined with ongoing research aimed at optimizing these compounds, pave the way for more efficient, safer therapies. Future developments will likely expand their application and efficacy, marking them as valuable assets in the fight against drug resistance and improving patient outcomes in both infectious diseases and oncology.

10. References

1. Bansal R, Aggarwal N, Kaur P. Synthesis and biological evaluation of novel trifluoromethyl quinazoline derivatives as potential antimalarial agents. J Med Chem. 2016;59(13):5995-6002.
2. Bansal Y, Kaur M, Kaur S. Pharmacological effects of quinazoline derivatives: A review. Eur J Med Chem. 2016;110:264-279. https://doi.org/10.1016/j.ejmech.2016.08.013
3. Bansal Y, Sharma M, Jain S, Bansal P. Pharmacological effects of quinazoline derivatives: A review. Eur J Med Chem. 2016;110:264-279. https://doi.org/10.1016/j.ejmech.2016.01.031
4. Gupta P, Bhowmick R, Mandal D. Quinazoline-based anticancer agents: overcoming drug resistance. Med Chem Commun. 2016;7(11):1995-2012.
5. Katritzky AR, Ramsden CA. The influence of substituents on the properties of heterocycles. Chem Soc Rev. 2008;37(4):811-829.
6. Lee CC, Zhang J, Wang X. The role of trifluoromethyl groups in enhancing drug activity and overcoming cancer resistance. J Med Chem. 2017;60(5):2273-2281.
7. Ranson M, Hammond LA, Ferry D. Erlotinib (Tarceva): efficacy and safety in cancer patients. Lancet Oncol. 2005;6(6):509-518.
8. Sharma A, *et al*. Recent developments in the synthesis of trifluoromethyl quinazoline derivatives. J Fluorine Chem. 2018;214:63-70.
9. Sharma A, Sahu SK, Mishra A. Recent developments in the synthesis of trifluoromethyl quinazoline derivatives. J Fluorine Chem. 2018;214:63-70. https://doi.org/10.1016/j.jfluchem.2018.08.012
10. Sharma N, Singh H, Arora D. Quinazoline-based antimalarials: synthesis and evaluation. Med Chem Res. 2018;27(1):124-136.
11. Wells TNC, Alonso PL, Gutteridge WE. Inhibitors of the malaria parasite: The state of play and future directions. Nat Rev Drug Discov. 2015;14(11):871-895. https://doi.org/10.1038/nrd2015.15
12. Wells TN, Kocken CH, Rottmann M. Inhibitors of the malaria parasite: The state of play and future directions. Nat Rev Drug Discov. 2015;14(11):871-895. https://doi.org/10.1038/nrd2018
13. Wells TNC, Hooft van Huijsduijnen R, van Voorhis WC. New approaches to antimalarial drug discovery. Trends Parasitol. 2015;31(11):688-696.
14. Woodburn JR, Geiger T. The role of the epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2000;6(10):3919-3927. https://clincancerres.aacrjournals.org/content/6/10/3919
15. Woodburn JR, Hynes NE. The role of the epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2000;6(10):3919-3927. https://clincancerres.aacrjournals.org/content/6/10/3919
16. Woodburn JR, *et al*. The role of the epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2000;6(10):3919-3927.

17. Woodburn JR, Waterfield MD, Hickson I. Gefitinib (Iressa): quinazoline-based EGFR inhibitor for cancer treatment. Cancer Res. 2000;60(24):7248-7257.
18. Zhang J, J A. Receptor tyrosine kinases as drug targets in cancer. Nat Rev Cancer. 2013;13(1):1-11. https://doi.org/10.1038/nrc3378
19. Zhang J, Reddy BB. Receptor tyrosine kinases as drug targets in cancer. Nat Rev Cancer. 2013;13(1):1-11. https://doi.org/10.1038/nrc3379
20. Zhang J, Wang X, MD. Receptor tyrosine kinases as drug targets in cancer. Nat Rev Cancer. 2013;13(1):1-11. https://doi.org/10.1038/nrc3378
21. Zhang Z, Zheng Y, Pan H. Quinazoline derivatives as anticancer agents: A review. Bioorg Med Chem Lett. 2013;23(3):327-335.
22. Zhao W, Wei J, Chen X. New quinazoline derivatives with anticancer activity. Eur J Med Chem. 2015;101:205-214.